此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours

2026年11月12日 更新者:GlaxoSmithKline

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of GSK5864399 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Selected Advanced Solid Tumours

This study will evaluate a new drug, GSK5864399, in adult participants with advanced solid tumours. The study will assess how well the drug works against cancer, how safe it is, how the body processes the drug, and its effect on the tumours.

研究概览

地位

尚未招聘

条件

干预/治疗

研究类型

介入性

注册 (估计的)

155

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Is at least 18 years of age or the legal age of consent.

  • Has histologically confirmed unresectable metastatic disease of either:

    • colorectal cancer that has progressed through at least 2 prior lines of systemic therapy
    • non-small cell lung cancer that has progressed through at least 1 prior line of systemic therapy
  • Has at least 1 target lesion per RECIST 1.1, as determined by the investigator.

  • Participants must provide Formalin-Fixed, Paraffin-Embedded (FFPE) tumour tissue sample taken from primary cancer or metastatic site.

  • Is willing to use adequate contraception.

  • Is capable of giving signed informed consent.

  • Has an ECOG performance status of 0 or 1.

  • Has adequate organ function.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria

  • Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months (with some exceptions).

  • Has had any major surgery within 28 days prior to first dose.

  • Has any history of prior allogeneic or autologous bone marrow transplant or other solid organ transplant.

  • Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

  • Has known active infectious disease or a serious infection within 4 weeks prior to the first dose.

  • Has a history (in prior year) of clinically significant or uncontrolled cardiovascular disease.

  • Has untreated brain or Central Nervous System (CNS) metastases or brain/CNS metastases that have progressed.

  • Any evidence of small cell or sarcomatoid histology for the NSCLC participants.

  • Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening.

  • Has any active renal condition.

  • Has a history of discontinuing prior treatment due to TEAE of ILD/pneumonitis

  • Has a history of (non-infectious) Interstitial Lung Disease (ILD)/pneumonitis that required active treatment within 4 weeks before study-intervention administration.

  • Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to Grade 1 or to the baseline status preceding prior therapy (with some exclusions).

  • Has any serious and/or unstable medical or psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of informed consent, or compliance to the study procedures.

  • Has symptomatic and/or progressive pleural metastases or cytologically confirmed malignant pleural effusions despite appropriate analgesia and thoracenteses respectively. Participants with previously treated pleural metastases/malignant pleural effusions with clinical stability demonstrated for at least 4 weeks prior to first dose are not excluded from participation.

  • Has received immunosuppressive agents within 30 days prior to first dose of study intervention (or requires long term [30 days or longer]).

  • Has received any prior therapy targeting CEACAM5.

  • Has received any live vaccine within 30 days of first dose. Vaccination against COVID-19 using vaccines that are authorized via the appropriate regulatory mechanisms (e.g., Emergency Use Authorization, Conditional Marketing Authorization, or Marketing Authorization Application) are not exclusionary. Messenger Ribonucleic acid (mRNA) and adenoviral-based COVID-19 vaccines are considered non-live. If a COVID-19 vaccine is administered at any time, the date of COVID-19 vaccination must be entered in the electronic Case Report Form (eCRF).

  • Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before first dose.

  • History of local radiotherapy within 2 weeks prior to the first dose of study intervention; more than 30% of bone marrow irradiation or extensive radiotherapy within 4 weeks before the first dose of study intervention.

  • Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of interventional medical research and/or has received treatment with any anticancer or investigational agent within 4 weeks prior to first dose. Participation in study follow-up part without IMP administration, non-interventional registry or epidemiological study is allowed.

  • Has a known Human Immunodeficiency Virus (HIV) infection AND meets at least one of the following criteria:

    • Has documented evidence of plasma HIV-1 Ribonucleic Acid (RNA) ≥50 c/mL within 3 months prior to or at screening. In the 3 to 12 months prior to screening, plasma HIV 1 RNA levels consistently <50 c/mL are required for enrollment; if multiple instances of plasma HIV-1 RNA values ≥50 c/mL occurred in the 3 to 12 months prior to screening, the participant is not eligible for enrollment unless, per the investigator's assessment, the elevations were neither persistent nor associated with antiretroviral resistance; OR
    • Has not had CD4 cell counts measured in the past 12 months (i.e., at least two separate measurements taken a minimum of 28 days apart, one of which must be conducted at screening); OR
    • Has had any CD4 cell count values ≤200 cells/mm3 in the past 12 months; OR
    • Has had one or more changes in their combination antiretroviral therapy regimen (except for switches as allowed per details provided in full protocol) or has received an antiretroviral therapy regimen that is inconsistent with locally recommended guidelines during the 3 months prior to screening; OR
    • Has a history of HIV-associated non-Hodgkin lymphoma within 5 years prior to screening or a history of HIV-associated invasive cervical cancer; OR
    • Has received treatment with an HIV 1 immunotherapeutic vaccine within 90 days of screening. Participants with history of CDC Stage 3 disease (also known as AIDS defining disease are eligible provided all other applicable criteria are met) if the AIDS-defining disease has been treated and cured or is stable for at least 3 months prior to screening. Cutaneous Karposi's Sarcoma not requiring systemic therapy is not exclusionary.
  • Is unable to adhere to the protocol-defined schedule of assessments, including requirements for the follow-up period of the study.

  • Has an Alanine Aminotransferase (ALT) or AST value >2.5x Upper Limit of Normal (ULN) and/or for participants with documented liver metastases/tumour infiltration has an ALT or AST value >5x ULN.

  • Has a total bilirubin value >1.5x ULN. Participants with Gilbert's syndrome can be included with a total bilirubin value >1.5x ULN, provided direct bilirubin is ≤1.5x ULN and participant otherwise meets entry criteria.

  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. Stable noncirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if the participant otherwise meets entry criteria.

  • Has documented presence of Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to the first dose of study intervention. In Japan, the following modification is applied; Has documented presence of HBsAg, HBcAb, or Hepatitis B surface antibody (HBsAb) (except for presence of HBsAb attributable to previous vaccination) at screening or within 3 months prior to the first dose of study intervention. For participants with presence of HBsAb, Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) will be tested every 3 months.

  • Has a positive Hepatitis C Virus (HCV) antibody test result at screening or within 3 months prior to the first dose of study intervention unless HCV RNA is negative, indicating past resolved HCV infection, including participants who have undergone curative treatment. Participants with a positive HCV antibody test result due to prior resolved disease, including those who have undergone curative HCV treatment, can be enrolled if a confirmatory negative HCV RNA test is obtained and the participant otherwise meets entry criteria.

  • Has a positive HCV RNA test result at screening or within 3 months prior to the first dose of study intervention. The HCV RNA test is optional, and participants with a negative HCV antibody test are not required to undergo HCV RNA testing as well.

  • Has baseline QT interval corrected for heart rate (QTc)>480 msec.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:第 1 部分:剂量递增

GSK5864399 will be administered

实验性的:第 2 部分:剂量扩展

GSK5864399 will be administered

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Part 1 & 2: Number of participants with Adverse events (AEs) by National Cancer Institute-Common terminology criteria for adverse events (NCI-CTCAE) Version 6.0
大体时间:Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1: Number of participants with Dose-Limiting Toxicities (DLTs)
大体时间:Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with changes in safety parameters
大体时间:Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) by severity
大体时间:Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with AEs leading to dose modifications
大体时间:Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with a change from baseline in body weight
大体时间:Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with a change from baseline in laboratory parameters (hematology, clinical chemistry and urinalysis)
大体时间:Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with a change from baseline in cardiac function: Electrocardiogram (ECG)
大体时间:Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status
大体时间:Up to approximately 155 weeks
Up to approximately 155 weeks
Part 2: Confirmed Objective Response Rate (cORR)
大体时间:Up to approximately 155 weeks

cORR is defined as the proportion of participants who have achieved a Best of response (BOR) of Complete Response (CR) or Partial Response (PR) as assessed by the Investigator and confirmed by repeat assessments at least 4 weeks after the initial response is documented, according to Response Evaluation Criteria in Solid Tumours (RECIST) version (v) 1.1.

Up to approximately 155 weeks

次要结果测量

结果测量
措施说明
大体时间
Part 1& 2: Maximum concentration (Cmax) of GSK5864399
大体时间:Up to approximately 161 weeks
Up to approximately 161 weeks
Part 1& 2: Time to maximum concentration (Tmax) of GSK5864399
大体时间:Up to approximately 161 weeks
Up to approximately 161 weeks
Part 1& 2: Area under the concentration-time curve (AUC) of GSK5864399
大体时间:Up to approximately 161 weeks
Up to approximately 161 weeks
Part 1& 2: Trough concentration (Ctrough) of GSK5864399
大体时间:Up to approximately 161 weeks
Up to approximately 161 weeks
Part 2: Progression-free survival (PFS)
大体时间:Up to approximately 161 weeks

PFS is defined as the time from date of randomization until the earliest date of documented disease progression as assessed by the Investigator according to RECIST1.1 or death due to any cause.

Up to approximately 161 weeks
Part 2: Duration of Response (DoR)
大体时间:Up to approximately 161 weeks

DoR is defined as the time from the date of the first documented objective response (CR/PR as assessed by the Investigator according to RECIST1.1) until the date of the first documented progression of disease (PD) or death, whichever is earlier.

Up to approximately 161 weeks
Part 1 & 2: Number of participants with Anti-drug antibodies (ADA) against GSK5864399
大体时间:Up to approximately 161 weeks
Up to approximately 161 weeks
Part 1 & 2: Titers of ADA against GSK5864399
大体时间:Up to approximately 161 weeks
Up to approximately 161 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月25日

初级完成 (估计的)

2029年11月16日

研究完成 (估计的)

2029年12月28日

研究注册日期

首次提交

2026年11月12日

首先提交符合 QC 标准的

2026年11月12日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD 共享时间框架

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD 共享访问标准

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅